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The study was run separately on two large primary care databases and the results were 
combined using meta-analysis techniques. Overall, there was good consistency in the 
results between the two databases. Because of the large number of comparisons in our 
study, the value for statistical significance was set at the 1% level. For the combined 
analysis we had 72 pairs of odds ratios, and the only significant heterogeneity discovered 
was for use of norgestimate compared with no use of combined oral contraceptives. 
 
The findings for norgestimate were of particular interest because of its historical position 
between second and third generation combined oral contraceptives. Although the results 
for the direct comparisons between norgestimate and levonorgestrel had different 
directions of association with VTE risk in the two databases, with a reduced odds ratio in 
favour of norgestimate) in CPRD (adjusted odds ratio 0.879, 95% confidence interval 
0.688 to 1.123, p-value 0.302) and an increased odds ratio in QResearch (adjusted odds 
ratio 1.252, 95% CI 0.996 to 1.573, p-value 0.054), neither of the findings were 
statistically significant. Results for these direct comparisons of norgestimate with 
levonorgestrel were not significantly heterogeneous between the databases (the p-value 
for this heterogeneity test was 0.038). The most reliable odds ratio is therefore the 
combined odds ratio from the fixed effect model (combined odds ratio 1.06, 95% CI 0.90 
to 1.26, p-value 0.480), which is very similar to that from the random effect model 
(combined odds ratio 1.08, 95% CI 0.89 to 1.30, p-value 0.443). 
 
We concluded, therefore, that this study had not produced evidence that the risk of VTE 
associated with norgestimate is significantly different from levonorgestrel. 
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